#United States #New York #Securities Fraud #Pomerantz Law #Sanara MedTech

Investigation on Behalf of Sanara MedTech Investors

Pomerantz LLP, a leading law firm based in New York, has initiated an investigation concerning Sanara MedTech, Inc. (NASDAQ: SMTI) and certain officers linked to the company. This inquiry comes in the wake of claims suggesting possible securities fraud and other unlawful practices in connection with the company’s recent financial disclosures.

Recent Developments

On November 11, 2025, Sanara announced a major restructuring, stating it would be discontinuing operations related to its Tissue Health Plus (THP) program. The management articulated that the decision aimed to reallocate resources towards its core surgical business to boost operational efficiency. This announcement was followed by a significant financial report on November 12, revealing a staggering net loss of $31.2 million from discontinued operations. Of this, an alarming $26.5 million was attributed to a noncash asset impairment related to the THP program's closure.

Consequently, these revelations prompted a drastic drop in Sanara's stock price, which plummeted by $6.93, equating to a 24.7% decline, ending at $21.11 per share on November 12. This steep decline has raised red flags among investors, leading to the ongoing investigation by Pomerantz LLP.

Pomerantz’s Role in Investor Protection

Pomerantz LLP has a distinguished reputation in the field of securities class action litigation, having been established over 85 years ago by the late Abraham L. Pomerantz, who is often referred to as the dean of the class action bar. The firm has consistently fought for the rights of investors facing corporate misconduct and fraud, achieving substantial recoveries in previous cases. As investors of Sanara MedTech face potential losses, Pomerantz aims to provide legal representation for those impacted by the recent downturn, reinforcing its commitment to uphold shareholder rights.

What Investors Should Do

Investors who believe they have suffered losses due to their investment in Sanara MedTech are encouraged to reach out to Pomerantz LLP. The firm is actively seeking individuals who wish to join this investigation into potential securities fraud or corporate misconduct by Sanara and its officers. Interested parties can contact Danielle Peyton via email at [email protected] or by phone at 646-581-9980, extension 7980.

In light of the ongoing investigation, it is crucial for investors to stay informed and consider their legal options. This situation underscores the importance of vigilance among investors, particularly in volatile sectors like biotechnology and medical technology.

For more information on joining the class action or the implications of the investigation, please visit Pomerantz's official website.

Conclusion

As the investigation unfolds, it highlights the critical intersection of business practices and legal compliance in the corporate world. The outcomes may not only affect current investors in Sanara but may also have broader implications for companies in the medical technology industry. Pomerantz LLP’s pursuit of justice in this case reinforces the necessity of accountability in corporate governance and securities practices.